Are you Dr. White?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 44 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
9200 W Wisconsin Ave
Division Of Neoplastic Diseases
Milwaukee, WI 53226Phone+1 414-805-6800Fax+1 414-805-6805
Summary
- Dr. Gilbert White, MD is an oncologist in Milwaukee, Wisconsin. He is currently licensed to practice medicine in Wisconsin and North Carolina. He is a Professor at Medical College of Wisconsin.
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 1975 - 1976- University of North Carolina HospitalsResidency, Internal Medicine, 1973 - 1975
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1971 - 1973
University of North Carolina at Chapel Hill School of MedicineClass of 1971
Certifications & Licensure
NC State Medical License 2022 - 2025
WI State Medical License 2005 - 2021- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1986
Clinical Trials
- Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease Start of enrollment: 1993 Oct 01
- Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency Start of enrollment: 1992 Mar 01
Publications & Presentations
PubMed
- Prothrombotic Antibodies Targeting the Spike Protein's Receptor-Binding Domain in Severe COVID-19.Wen Zhu, Yongwei Zheng, Mei Yu, Nathan Witman, Lu Zhou
Blood. 2024-11-22 - 5 citationsPaxillin binding to the PH domain of kindlin-3 in platelets is required to support integrin αIIbβ3 outside-in signalingHuong T. T. Nguyen, Zhen Xu, Xiaofeng Shi, Shuzhen Liu, Marie L. Schulte
Journal of Thrombosis and Haemostasis. 2021-08-31 - 4 citationsSARS-CoV-2 receptor binding domain-specific antibodies activate platelets with features resembling the pathogenic antibodies in heparin-induced thrombocytopeniaWen Zhu, Yongwei Zheng, Mei Yu, Jianhui Wei, Yongguang Zhang
Research Square. 2021-04-26
Press Mentions
Wisconsin Researchers Awarded $5.3 Million for NIH Precision Medicine ResearchAugust 31st, 2017
Grant Support
- Research Training In Transfusion MedicineNational Heart, Lung, And Blood Institute2010–2011
- Blood Dyscrasias And Transfusion MedicineNational Heart, Lung, And Blood Institute2010
- Initiative In Stem Cell BiologyNational Center For Research Resources2010
- Role Of Carboxyterminal Hypervariable Region In Rap1b FunctionNational Heart, Lung, And Blood Institute2009–2010
- The Role Of RAP1 In Integrin Activation And Platelet SignalingNational Heart, Lung, And Blood Institute2006–2007
- Administrative CoreNational Heart, Lung, And Blood Institute2006
- Extension Study To Characterize Bddrfviii Manufactured By Refacto AFNational Center For Research Resources2005
- Role Of Rap1b In Integrin Activation And Platelet SignalingNational Heart, Lung, And Blood Institute2004–2005
- Core A-- Adminsitrative CoreNational Heart, Lung, And Blood Institute2004
- Transfusion Medicine/Hemostasis Clinical Research Netwo*National Heart, Lung, And Blood Institute2002–2003
- Structure And Function Of Vascular IntegrinsNational Heart, Lung, And Blood Institute1993–2003
- Recombinant Factor VIII SQ In Previously Treated Hemophilia ANational Center For Research Resources1999–2002
- R97 022: Intron A + Ribavirin For Hepatitis C &Inherited Coagulation DiseaseNational Center For Research Resources1999–2002
- Antihemophilic Factor (Af Rahf) In Prev Treated Severe Hemophilia ANational Center For Research Resources1999–2002
- Structure And Function Of The Beta Cytoplasmic DomainsNational Heart, Lung, And Blood Institute1998–2002
- Structure/Function Of Vascular IntegrinsNational Heart, Lung, And Blood Institute1997–2002
- Predictors Of Inhibitors In Hemophilia ANational Center For Research Resources2000
- Factor VIII Vector For Treatment Of Severe Hemophilia ANational Center For Research Resources2000
- Antiretriviral Therapy &Indinavir Sulfate In HIV-1 HemophiliaNational Center For Research Resources2000
- Platelet Specific Knockout Of Signaling ProteinsNational Heart, Lung, And Blood Institute1997–2000
- Comparing Recombinant Factor VIII VS Hemofil(R)-M In HemophiliaNational Center For Research Resources1997–1999
- Three Segment Phase I/II Study In Previously Treated Hemophilia BNational Center For Research Resources1996–1999
- Internatl Symposium On Gene Therapy For HemophiliaNational Heart, Lung, And Blood Institute1997
- Study Of R-Viii SQ In Hemophilia A Patients During SurgeryNational Center For Research Resources1997
- Recombinant Human Factor IX In Previously Treated Patients With Hemophilia BNational Center For Research Resources1997
- Recombinant Factor VIII In The Treatment Of Previously Treated Hemophilia A PTSNational Center For Research Resources1997
- Ligand Binding Domains Of Vascular IntegrinsNational Heart, Lung, And Blood Institute1995–1997
- Recombinant Factor VIII In Treatment Of Previously Treated Hemophilia A PatientsNational Center For Research Resources1995–1997
- Genetics Institute Protocol C9417-21--Recombinant Human Factor IXNational Center For Research Resources1996
- Effect Of Bleeding Time And Calculation Of Von Willebrand FactorNational Center For Research Resources1995
- Molecular Biology Of Cytoadhesins--Oral Tissue ModelNational Institute Of Dental &Craniofacial Research1987–1990
